IP Library Granted Patent US 9,187,490
Granted Patent B2
US 9,187,490 · App. 14/336,531 · Granted Nov 17, 2015

Dimeric IAP inhibitors

Inventors: Stephen M. Condon (Glenmoore, PA); Matthew G. Laporte (Honey Brook, PA); Yijun Deng (Dresher, PA); Susan R. Rippin (Wilmington, DE)
Assignee: TetraLogic Birinapant UK Ltd.
C07D487/14C07D403/14C07D405/14C07D409/14C07K5/0606C07K5/06026A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,490
App. No.
14/336,531
Granted
Nov 17, 2015
Kind
B2
Abstract

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.

Claims (44)

1. A method for inducing apoptosis in a cell comprising contacting the cell with a compound selected from the group consisting of compounds of formula (IV), (V), and (VI) and with TRAIL or another TRAIL receptor agonist, in amounts sufficient to induce apoptosis in the cell

where R5a and R5b are independently H, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; or each optionally-substituted with hydroxyl, mercapto, halogen, amino, carboxyl, alkyl, haloalkyl, alkoxy, or alkylthio; or, optionally, R5a and R5b are connected by an alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon atoms or an optionally-substituted alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S;

where R7a and R7b are independently H, alkyl, cycloalkyl, haloalkyl; or R8a and R7a and R8b and R7b can independently or together form a ring;

R8a and R8b are independently H, hydroxyl, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or heteroarylalkyl wherein each alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, and heteroarylalkyl is optionally-substituted with halogen, hydroxyl, mercapto, carboxyl, alkyl, alkoxy, amino, and nitro; or R8a and R7a and R8b and R7b independently or together form a ring;

R3a and R3b are independently H, halogen, alkyl, aryl, arylalkyl, amino, arylamino, arylalkylamino, hydroxy, alkyloxy, aryloxy, arylalkylhydroxy, dialkylamino, amido, sulfonamido, or amidino;

m and n are independently 0, 1, 2, or 3;

X and Y are independently O, N, S, or C═C and;

R12a, R12b, R13a, R13b, R14a, R14b are, independently, H, Cl, Br, F, alkyl, cycloalkyl, hydroxyl, alkoxy, amino, alkylamino, cyano, or CO 2 H; and

wherein Wa and Wb together are a bond, alkylene, alkenylene, alkynylene, aryl, arylalkylene, arylalkylalkylene, heteroaryl, heteroarylalkylene, or an optionally-substituted alkylene, alkenylene, alkynylene chain of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S; and R11a and R11b are independently absent, H, alkyl, optionally-substituted alkyl, hydroxyalkyl, alkoxyalkyl; or R11a and R11b together form an alkylene, alkenylene, alkynylene, or alkyloxyalkylene chain of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S;

where R5a and R5b are independently H, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; or each optionally-substituted with hydroxyl, mercapto, halogen, amino, carboxyl, alkyl, haloalkyl, alkoxy, or alkylthio; or, optionally, R5a and R5b are connected by an alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon or optionally-substituted alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S;

where R7a and R7b are independently H, alkyl, cycloalkyl, haloalkyl; or R8a and R7a and R8b and R7b can independently or together form a ring;

R8a and R8b are independently H, hydroxyl, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or heteroarylalkyl wherein each alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, and heteroarylalkyl is optionally-substituted with halogen, hydroxyl, mercapto, carboxyl, alkyl, alkoxy, amino, and nitro; or R8a and R7a and R8b and R7b can independently or together form a ring:

R3a and R3b are independently H, halogen, alkyl, aryl, arylalkyl, amino, arylamino, arylalkylamino, hydroxy, alkyloxy, aryloxy, arylalkylhydroxy, dialkylamino, amido, sulfonamido, or amidino;

m and n are independently 0, 1, 2, or 3; and

R12a, R12b, R13a, R13b, R14a, R14b are independently H, Cl, Br, F, alkyl, cycloalkyl, hydroxyl, alkoxy, amino, alkylamino, cyano, or CO 2 H; and

Wa and Wb together are a bond, alkylene, alkenylene, alkynylene, aryl, arylalkylene, arylalklylalkylene, heteroaryl, heteroarylalkylene, or an optionally-substituted alkylene, alkenylene, alkynylene chain of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S; and R11a and R11b independently H, alkyl, optionally-substituted alkyl, hydroxyalkyl, alkoxyalkyl; or R11a and R11b together form an alkylene, alkenylene, alkynylene, or alkyloxyalkylene chain of 2 to 12 or optionally-substituted alkylene, alkenylene, alkynylene or alkyloxyalkylene chain of 2 to 12 carbon atoms where one or more carbon atoms is replaced with N, O, or S; and

where R5a and R5b are independently H, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; or each optionally-substituted with hydroxyl, mercapto, halogen, amino, carboxyl, alkyl, haloalkyl, alkoxy, or alkylthio; or, optionally, R5a and R5b are connected by an alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon atoms or optionally-substituted alkylene, alkenylene, alkynylene bridge of 2 to 12 carbon atoms where one or more carbon atoms can be replaced with N, O, or S;

where R7a and R7b are independently H, alkyl, cycloalkyl, haloalkyl: or R8a and R7a and R8b and R7b can independently or together form a ring;

R8a and R8b are independently H, hydroxyl, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or heteroarylalkyl wherein each alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, and heteroarylalkyl is optionally-substituted with halogen, hydroxyl, mercapto, carboxyl, alkyl, alkoxy, amino, and nitro; or R8a and R7a and R8b and R7b can independently or together form a ring;

R3a and R3b are independently H, halogen, alkyl, aryl, arylalkyl, amino, arylamino, arylalkylamino, hydroxy, alkyloxy, aryloxy, arylalkylhydroxy, dialkylamino, amido, sulfonamido, or amidino;

X is O, N, S, or C═C; and

R12a, R12b, R13a, R13b, R14a, R14b are independently H, CI, Br, F, alkyl, cycloalkyl, hydroxyl, alkoxy, amino, alkylamino, cyano, or CO 2 H; and

wherein Wa is H, Cl, Br, F, alkyl, CN, or CO 2 H; Wb and R11a together are a bond, alkylene, alkenylene, alkynylene, aryl, arylalkylene, arylalkylalkylene, heteroaryl, heteroarylalkylene, or an optionally-substituted alkylene, alkenylene, alkynylene chain of 2 to 12 carbon atoms where one or more carbon atoms is replaced with N, O, or S; and R11b is absent or H, alkyl, optionally-substituted alkyl, hydroxyalkyl, alkoxyalkyl.

2. The method of claim 1 that comprises contacting the cell with a compound selected from the compounds of Formula (IV) wherein

X and Y are both —N—

R3a and R3b are independently H, hydroxy, alkyloxy, aryloxy, alkylamino, dialkylamino, amido, sulfonamido, or amidino;

R5a and R5b are independently methyl, ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cycloalkyl, aryl, or arylalkyl, each optionally substituted with alkoxyl or hydroxyl; and

R7a and R7b are independently methyl, fluoromethyl, difluoromethyl, ethyl, fluoroethyl, or cycloalkyl.

3. The method of claim 1 that comprises contacting the cell with a compound selected from the compounds of Formula (V) wherein

R3a and R3b are H, hydroxy, alkyloxy, aryloxy, alkylamino, dialkylamino, amido, sulfonamido, or amidino;

R5a and R5b are methyl, ethyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cycloalkyl, aryl, or arylalkyl, each optionally substituted with alkoxyl or hydroxyl;

R7a and R7b are methyl, fluoromethyl, difluoromethyl, ethyl, fluoroethyl, or cycloalkyl;

R8a and R8b are independently —H or alkyl;

Wa and Wb are either a bond or

and wherein the substituents R5a and R5b are identical, the substituents R7a and R7b are identical, the substituents R8a and R8b are identical, the substituents R3a and R3b are identical, the substituents R11a and R11b are identical, the substituents R12a and R12b are identical, the substituents R13a and R13b are identical and the substituents R14a and R14b are identical.

4. The method of claim 1 that comprises contacting the cell with a compound selected from the compounds of Formula (VII):

where R5a and R5b are the same and are an alkyl, an alkyl substituted with hydroxyl, or an alkyl substituted with alkoxy;

where R7a and R7b are the same and are alkyl;

where R8a and R8b are the same and are selected from H, or alkyl;

where R3a and R3b are the same and are selected from H, or hydroxy;

where R12a, and R12b are both H;

where R13a and R13b are the same and are selected from H, or F; and

where, R14a and R14b are both H.

5. The method of claim 4 wherein the cell is a bladder cancer cell, breast cancer cell, prostate cancer cell, lung cancer cell, pancreatic cancer cell, gastric cancer cell, colon cancer cell, ovarian cancer cell, renal cancer cell, hepatoma cell, melanoma cell, lymphoma cell, or sarcoma cell, in a patient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2021
From: CONDON, STEPHEN M.; LAPORTE, METTHEW G.; DENG, YIJUN; RIPPIN, SUSAN R.
To: TETRALOGIC PHARMACEUTICALS CORPORATION
Reel/Frame 056475/0094 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 047436 FRAME: 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 7, 2021
From: TETRALOGIC BIRINAPANT UK LTD
To: MEDIVIR AB
Reel/Frame 056597/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: TETRALOGIC BIRINAPANT UK
To: MEDIVIR AB
Reel/Frame 047436/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: TETRALOGIC PHARMACEUTICALS CORPORATION
To: TETRALOGIC BIRINAPANT UK LTD
Reel/Frame 036264/0713 →
Continuity (10)
Continuation 13925960 · Jun 25, 2013
Continuation 13196202 · Aug 2, 2011
Continuation 12403915 · Mar 13, 2009
Continuation 11363387 · Feb 27, 2006
Provisional Application 60729853 · Oct 25, 2005
Provisional Application 60706649 · Aug 9, 2005
Provisional Application 60692111 · Jun 20, 2005
Provisional Application 60668344 · Apr 5, 2005
Provisional Application 60656201 · Feb 25, 2005
Related Publication 20140329823A1 · Nov 6, 2014